Search
Now showing items 1-4 of 4
Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa
(Nature Publishing Group, 2018)
HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to
characterize the HIV-1 IN gene in a South African context and identify resistance-associated mutations
(RAMs) against ...
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C integrase-dolutegravir binding
(Public Library of Science, 2020)
Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand transfer inhibitors (INSTIs) have proven to be a ...
Structural comparison of diverse HIV-1 subtypes using molecular modelling and docking analyses of integrase inhibitors
(MPDI, 2020)
The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme targeted by several drugs; ...
Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa
(Frontiers Media S.A., 2020)
The South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since it was first introduced. HIV-1 drug resistance can hamper the ...